Suppr超能文献

基于分子动力学模拟和结合能计算研究 HIV-1 蛋白酶 M46I 突变诱导的沙奎那韦耐药的耐药机制。

Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.

机构信息

Molecular Signaling & Drug Discovery Laboratory, Department of Biochemistry, Central University of Punjab, Bathinda 151401, Punjab, India.

Department of Urology, Pharmacology and Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.

出版信息

Viruses. 2022 Mar 28;14(4):697. doi: 10.3390/v14040697.

Abstract

Drug-resistance-associated mutation in essential proteins of the viral life cycle is a major concern in anti-retroviral therapy. M46I, a non-active site mutation in HIV-1 protease has been clinically associated with saquinavir resistance in HIV patients. A 100 ns molecular dynamics (MD) simulation and MM-PBSA calculations were performed to study the molecular mechanism of M46I-mutation-based saquinavir resistance. In order to acquire deeper insight into the drug-resistance mechanism, the flap curling, closed/semi-open/open conformations, and active site compactness were studied. The M46I mutation significantly affects the energetics and conformational stability of HIV-1 protease in terms of RMSD, RMSF, Rg, SASA, and hydrogen formation potential. This mutation significantly decreased van der Waals interaction and binding free energy (∆G) in the M46I-saquinavir complex and induced inward flap curling and a wider opening of the flaps for most of the MD simulation period. The predominant open conformation was reduced, but inward flap curling/active site compactness was increased in the presence of saquinavir in M46I HIV-1 protease. In conclusion, the M46I mutation induced structural dynamics changes that weaken the protease grip on saquinavir without distorting the active site of the protein. The produced information may be utilized for the discovery of inhibitor(s) against drug-resistant HIV-1 protease.

摘要

耐药相关突变在病毒生命周期的必需蛋白中是抗逆转录病毒治疗的主要关注点。HIV-1 蛋白酶中的非活性部位突变 M46I 已在临床上与 HIV 患者的沙奎那韦耐药相关。进行了 100ns 的分子动力学(MD)模拟和 MM-PBSA 计算,以研究基于 M46I 突变的沙奎那韦耐药的分子机制。为了更深入地了解耐药机制,研究了瓣卷曲、闭合/半开/打开构象以及活性部位紧凑性。M46I 突变在 RMSD、RMSF、Rg、SASA 和氢键形成潜力方面,对 HIV-1 蛋白酶的能量和构象稳定性有显著影响。该突变显著降低了 M46I-沙奎那韦复合物中范德华相互作用和结合自由能(∆G),并在大多数 MD 模拟期间诱导瓣向内卷曲和瓣更宽的打开。主要的开放构象减少,但在 M46I HIV-1 蛋白酶中存在沙奎那韦时,瓣向内卷曲/活性部位紧凑性增加。总之,M46I 突变诱导的结构动力学变化削弱了蛋白酶对沙奎那韦的抓握,而不会扭曲蛋白质的活性部位。所产生的信息可用于发现针对耐药 HIV-1 蛋白酶的抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04df/9031992/0ad23ec8a911/viruses-14-00697-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验